



10745 Westside Way, Suite 200

Alpharetta, GA 30009

Tel: +1 (844) 884 5367

Email: [info@vtivision.com](mailto:info@vtivision.com)

[www.vtvision.com](http://www.vtvision.com)

[www.vtvisioninvestors.com](http://www.vtvisioninvestors.com) (for investors)

## ASX Announcement

### ***Visioneering Technologies, Inc. Creates Educational Series for Eye Care Practitioners***

The first installment discusses treatment of children in clinical practice and features insights from world leading researchers and clinicians.

#### **Highlights**

- Visioneering has announced the creation of a new educational series for eye care practitioners featuring some of the world's leading researchers and clinicians
- The first installment of the VTI / NaturalVue video series includes thoughts from Prof Earl Smith, Dr Nicola Anstice, Prof Padmaja Sankaridurg, Dr Kate Gifford, and Dr Sally Dillehay
- The educational series is free for eye care practitioners and can be accessed via: [www.vtvision.com/global/educationalseries](http://www.vtvision.com/global/educationalseries).

**Atlanta, GA, 15 April 2019**, US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses **Visioneering Technologies, Inc (ASX: VTI)** ('Visioneering' or 'The Company') announces the creation of a new educational series for eye care practitioners featuring some of the world's leading researchers and clinicians.

The first installment of the VTI / NaturalVue video series highlights the following speakers and topics:

- Prof Earl Smith, Researcher, University of Houston, United States – Impact of Eye Growth, Disease States
- Dr Nicola Anstice – Researcher, University of Canberra, Australia – Contact Lenses and Safety with Children
- Prof Padmaja Sankaridurg, Researcher, Brien Holden Vision Institute, Australia – Future Prevalence and Implications of Myopia
- Dr Kate Gifford, Clinician-Scientist & Peer Educator, Australia – Helping Parents Manage Childhood Myopia
- Dr Sally Dillehay, Clinical Researcher & Optometrist, (and former VTI employee) United States – Disease States and Impact of Genetics

Peg Achenbach, OD, FAAO, Vice President, Professional Services and Clinical Science for VTI, said, "These informational videos from the leading clinicians and researchers in the contact lens industry offer education and insight into some of the most pertinent and cutting-edge topics today. We are in the midst of an information explosion in our profession and these videos will help practitioners stay informed and up to date in myopia, pediatric contact lens fitting, contact lens safety, and genetics. This informational series is part of our continuing commitment to the education of practitioners to raise the level of clinical excellence and increase the body of knowledge for our profession."

The educational series is free for eye care practitioners and can be accessed via: <https://vtivision.uk/practitioners/educational-video-series/>.

The company plans to continue to expand the series in the near future with installments featuring other well-known clinicians and researchers including Prof Lyndon Jones, Dr Tom Arnold, Dr Jeff Cooper, Dr Brett O'Connor and Dr Tom Aller and will include more on managing children and presbyopic adults in practice.

**For more information, please contact:**

<b>Company</b>	<b>Investor and media relations</b>
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: <a href="mailto:ssnowdy@vtivision.com">ssnowdy@vtivision.com</a>	Julia Maguire The Capital Network M: +61 419 815 386 E: <a href="mailto:julia@thecapitalnetwork.com.au">julia@thecapitalnetwork.com.au</a>

*This information may describe uses for multifocal contact lenses that have not been approved or cleared by the FDA for use in the United States.*

**NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens Indication for Use in Europe and Australia and New Zealand:** NaturalVue (etafilcon A) Multifocal Daily Disposable Soft (Hydrophilic) Contact Lenses are indicated for daily wear for the correction of refractive ametropia (myopia and hyperopia) and/or presbyopia, and myopia progression control in aphakic and/or non-aphakic persons with non-diseased eyes in powers from -20.00 to +20.00 dioptres and with non-diseased eyes who may require a reading addition of up to +3.00D. The lenses may be worn by persons who exhibit astigmatism of 2.00 dioptres or less that does not interfere with visual acuity.

**About VTI:**

Visioneering Technologies Inc. (ASX: VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.

Headquartered in the US, Visioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® Multifocal contact lens, and VTI has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the United States, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

**Foreign Ownership Restriction:**

VTI's CHESSE Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of VTI's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

**Forward-Looking Statements:**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product as well as, our expectations with respect to our ability to develop and commercialize new products.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

MKT-VTI-ASX9 r0